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Abstract
Background: Emergency department attendances with chest pain requiring assessment for acute coronary syndrome
(ACS) are a major global health issue. Standard assessment includes history, examination, electrocardiogram
(ECG) and serial troponin testing. Computerised tomography coronary angiography (CTCA) enables additional
anatomical assessment of patients for coronary artery disease (CAD) but has only been studied in very low-risk patients.
This trial aims to investigate the effect of early CTCA upon interventions, event rates and health care costs in patients
with suspected/confirmed ACS who are at intermediate risk.
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Methods/design: Participants will be recruited in about 35 tertiary and district general hospitals in the UK.
Patients ≥18 years old with symptoms with suspected/confirmed ACS with at least one of the following will
be included: (1) ECG abnormalities, e.g. ST-segment depression >0.5 mm; (2) history of ischaemic heart
disease; (3) troponin elevation above the 99th centile of the normal reference range or increase in high-
sensitivity troponin meeting European Society of Cardiology criteria for ‘rule-in’ of myocardial infarction (MI).
The early use of ≥64-slice CTCA as part of routine assessment will be compared to standard care. The
primary endpoint will be 1-year all-cause death or recurrent type 1 or type 4b MI at 1 year, measured as the
time to such event. A number of secondary clinical, process and safety endpoints will be collected and
analysed. Cost effectiveness will be estimated in terms of the lifetime incremental cost per quality-adjusted
life year gained. We plan to recruit 2424 (2500 with ~3% drop-out) evaluable patients (1212 per arm) to have
90% power to detect a 20% versus 15% difference in 1-year death or recurrent type 1 MI or type 4b MI,
two-sided p < 0.05. Analysis will be on an intention-to-treat basis. The relationship between intervention and
the primary outcome will be analysed using Cox proportional hazard regression adjusted for study site (used
to stratify the randomisation), age, baseline Global Registry of Acute Coronary Events score, previous CAD and
baseline troponin level. The results will be expressed as a hazard ratio with the corresponding 95%
confidence intervals and p value.
Discussion: The Rapid Assessment of Potential Ischaemic Heart Disease with CTCA (RAPID-CTCA) trial will
recruit 2500 participants across about 35 hospital sites. It will be the first study to investigate the role of
CTCA in the early assessment of patients with suspected or confirmed ACS who are at intermediate risk and
including patients who have raised troponin measurements during initial assessment.
Trial registration: ISRCTN19102565. Registered on 3 October 2014. ClinicalTrials.gov: NCT02284191.
Keywords: Acute coronary syndrome, Chest pain assessment, CT coronary angiogram, Cardiac CT
Background
Emergency department (ED) attendances with chest pain
requiring assessment for acute coronary syndrome
(ACS) are a major global health issue. In the USA there
are eight million attendances annually with chest pain
[1], and yet most are ultimately discharged home with-
out a definitive diagnosis [2]. In the UK approximately
700,000 patients present annually to EDs with chest pain
in England and Wales, resulting in around 350,000 emer-
gency admissions [3]. Most of these patients present with,
and are subsequently admitted for, evaluation of suspected
ACS. This is becoming an increasing problem; chest pain
admissions have doubled in the last decade, accounting
for approximately 5% of all emergency admissions (the
most common reason for acute hospital admission), whilst
those for angina or ACS have fallen [4, 5]. Therefore, most
patients admitted with suspected ACS are discharged
without the condition being confirmed by subsequent
investigation. Despite this, confirmed ACS remains a
common diagnosis and is associated with major adverse
outcomes.
Diagnostic pathways for suspected ACS
Due to the consequences of inadvertent discharge of a
patient with missed ACS and the limitations of initial
clinical assessment, most patients with suspected ACS
will require diagnostic investigation and a short hospital
admission or a period of observation in the ED. This
assessment and evaluation period in the UK is based on
national and international guidelines [6–8] and includes
serial cardiac biomarkers, typically troponin I or T, and
a 12-lead electrocardiogram (ECG). Many troponin
assays do not reach maximal sensitivity until 12 hours
after chest pain onset, although newer high-sensitivity
assays are increasingly used and recommended in contem-
porary guidelines [8]. Current European guidelines suggest
presentation and 3-hour measurements of high-sensitivity
troponin to rule in or rule out myocardial infarction (MI)
in the ED, depending on the time since chest pain onset.
This is supported by recent large cohort studies, assessing
the diagnostic characteristics of high-sensitivity troponin
at the limit of detection, showing exceptional negative pre-
dictive value for presentation samples [9]. These novel,
highly sensitive troponin assays, along with suggested
lower diagnostic and sex-specific thresholds of contem-
porary assays [10–12], will increase the number of patients
with an elevated troponin result. Patients with an elevated
troponin who present with suspected ACS will have sus-
tained an acute MI according to the Universal Definition
of MI [13]. Current recommendations are that these indi-
viduals should receive relevant management including
invasive coronary angiography (ICA) within 24 hours of
diagnosis [8], leading to a significant number of patients
internationally requiring transfer to a percutaneous
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coronary intervention (PCI) centre for continued care.
A further potential disadvantage of highly sensitive
troponin assays and lower diagnostic thresholds of con-
temporary assays is the increased number of patients
who have raised troponins but do not have coronary
thrombosis and therefore do not require potent antithrom-
botic therapy and ICA. These may be related to cardiac
(myocarditis, arrhythmia, stress-induced cardiomyopathy)
or other conditions such as pulmonary embolism as well as
type 2 MI [8, 12]. The unanticipated consequence of
this may be increased numbers of patients receiving
further investigation for ACS including ICA with con-
sequent patient distress, risk and cost. Subsequent as-
sessment to further delineate ischaemic heart disease,
especially if ECG and troponin testing are negative,
includes functional or anatomical testing. Further in-
vestigations to delineate future prognosis rather than
immediate diagnosis are inconsistent in the UK [14],
resulting in many patients being discharged from hos-
pital with ’troponin-negative chest pain’ and no clear
alternative diagnosis. This leads to many patients and
clinicians feeling unclear about what to do if the patient
has recurrent symptoms, since coronary artery disease
(CAD) has not been unequivocally excluded. Elsewhere,
ancillary testing during or soon after the ED attendance
is widely adopted, leading to prolonged lengths of stay
and significant cost [2].
ICA is recommended by the European Society of
Cardiology (ESC) in confirmed ACS or for those
patients believed to be at high risk of obstructive
CAD, but it is costly and associated with a small but
significant major complication rate, including death
[8, 14]. It often requires the transfer of patients be-
tween hospitals; e.g. in the UK only around 35% of
acute hospitals have on-site revascularisation facilities
[15]. It is unknown how many patients receive un-
necessary ICA, but it is likely to be a significant and
potentially increasing number, if all patients with a
raised troponin and chest pain receive ICA. Some
patients with confirmed ACS do not receive ICA
due to limited availability, belief that troponin eleva-
tion is due to an alternative condition or other rea-
sons for a decision to pursue non-invasive
management. It could be argued that the benefits of
an invasive approach have not been established in
patients who would have been deemed low risk be-
fore the advent of high-sensitivity troponin assays.
On this basis, patients with suspected ACS could be
investigated by CTCA, with onward referral for PCI
or coronary artery bypass graft (CABG) surgery lim-
ited to patients with clearly treatable coronary ob-
struction. Indeed, CTCA has a similar discriminatory
value in determining the need for coronary revascu-
larisation as ICA [16].
CT coronary angiography in chest pain assessment
CTCA has the potential to be a quicker, simpler,
substantially cheaper and more readily delivered alter-
native to ICA and should translate into a highly ef-
fective and safe imaging strategy. A systematic review
of 21 diagnostic accuracy studies of CTCA reported a
pooled sensitivity of 99% and a specificity of 89% for
detection of CAD [17]. A further recent meta-analysis
of eight diagnostic cohort studies of CTCA in sus-
pected ACS [18] reported a sensitivity of 94% (95%
predictive interval 61–99%) and a specificity of 87%
(95% predictive interval 16–100%), but decision ana-
lysis modelling was unable to draw reliable conclu-
sions about the clinical and cost effectiveness of
CTCA in suspected ACS. Three recent trials from
the USA investigating CTCA in patients with chest
pain presenting to the ED promote its use and wide-
spread adoption [19–21]. Meta-analyses of four trials
[22, 23] conclude that CTCA is safe, cost effective
and associated with reduced hospital length of stay
in the US health care system. However, the clinical
event rates in these studies are low, with no differ-
ence between trial arms. Moreover, the participants
had relatively long hospital stays and many add-
itional tests compared with other international health
care settings.
CTCA enables non-invasive anatomical quantifica-
tion of CAD [2]. This allows accurate identification of
patients who may benefit from coronary revascularisa-
tion [16] and more accurately targets patients for pri-
mary or secondary therapies, thus improving clinical
outcomes. In those patients without disease, it may
reduce hospital stay and recurrent hospitalisation as
well as improve patient satisfaction due to clarity on
the absence of CAD. However, if CTCA use results in
an increase in ICA as a result of false positive or
equivocal results in low-risk patients, it may increase
the cost and risk without clinical benefit.
Since the start of the Rapid Assessment of Poten-
tial Ischaemic Heart Disease with CTCA (RAPID-
CTCA) trial, five trials investigating the role of
CTCA in stable CAD (the PROMISE, SCOT-HEART
and CAPP trials) [24–26] and patients with negative
troponin results and normal ECGs admitted for as-
sessment of ACS (the CATCH and BEACON trials)
[27–29] have been reported. All show promising re-
sults for the impact of CTCA on improving longer
term clinical outcomes [30]. All consistently show a
decreased rate of normal ICA, and the three studies
reporting longer term outcomes are consistent in
suggesting improved cardiovascular outcomes, in-
cluding mortality, although these are all secondary
analyses. None have been powered on relevant short
or longer term important clinical outcomes.
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However, early CTCA needs investigation in pa-
tients at intermediate risk for ACS, for whom
improved and optimal targeting of interventions, in-
cluding coronary revascularisation, and primary and
secondary preventive therapy is likely to improve
diagnosis and longer term outcome. The clinical and
cost effectiveness of early CTCA in suspected or
confirmed ACS must be clearly demonstrated before
adoption of the technology into routine clinical prac-
tice, given its cost, risk and uncertainty of benefit. A
positive or negative trial is equally important.
The aims of the RAPID-CTCA trial
This study aims to investigate the effect of early
CTCA in patients with suspected or confirmed ACS
presenting to the ED, Medical Assessment Units
(MAUs) or cardiology department, upon interven-
tions, event rates and health care costs in a pragmatic
clinical trial with economic evaluation up to 1 year
after the trial intervention.
Methods/design
RAPID-CTCA is an open, prospective, parallel-group,
1:1 randomised controlled trial of CTCA in addition to
standard care (CTCA) versus standard care only (SCO)
in adults presenting to the ED, MAU or cardiology de-
partment with suspected or confirmed ACS. Recruit-
ment will take place in approximately 35 tertiary and
district hospitals (with and without on-site ICA facilities)
with ED, MAU, radiology and cardiology services.
Participants allocated to the CTCA arm will receive the
scan during the initial admission or, if discharged, as an
ambulatory patient within 72 hours of randomisation.
All participants will be followed up for 1 year. Figure 1
details the patient pathway from screening for eligibil-
ity to the end of follow-up.
Primary endpoint
The primary endpoint will be all-cause death or recur-
rent non-fatal type 1 or type 4b MI at 1 year, measured
as the time to the first such event. MI will be defined ac-
cording to the most recent Universal Definition [13] and
will be adjudicated by two independent cardiologists
blinded to the intervention.
Secondary endpoints
Table 1 describes the secondary endpoints.
Population
The study population consists of patients ≥18 years
old with symptoms mandating investigation for
suspected or confirmed ACS with at least one of the
following: ECG abnormalities, e.g. ST-segment depres-
sion >0.5 mm; history of ischaemic heart disease
(where the clinician assessing patient confirms history
based on patient history or available records); or
troponin elevation above the 99th centile of the nor-
mal reference range or increase in high-sensitivity
troponin meeting ESC criteria for ‘rule-in’ of myocar-
dial infarction (troponin assays will vary from site to
Fig. 1 Patient pathway
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site; local laboratory reference standards will be used).
Table 2 lists the exclusion criteria.
Patient selection and enrolment
All potentially eligible patients are screened for eligi-
bility by trained members of the research or clinical
teams using triage information and clinical or elec-
tronic records in the ED, MAU or cardiology
department. No additional trial-specific screening
tests will be performed. The patient will receive rou-
tine acute clinical assessment including, as a mini-
mum, a 12-lead ECG, vital signs measurement (pulse
rate, non-invasive blood pressure, respiratory rate,
conscious level, oxygen saturations and skin prick
blood sugar) and admission routine blood tests in-
cluding troponin and renal function. The results of
Table 1 Secondary endpoints
1. Clinical, process and
patient-centred endpoints
• Hospital length of stay
• Coronary care length of stay
• Proportion of patients receiving invasive coronary angiography (ICA) during index
hospitalisation
• Proportion of patients receiving coronary revascularisation during index hospitalisation
• Proportion of patients receiving subsequent unplanned coronary revascularisation after
index hospitalisation within 12 months
• Proportion of patients in CTCA arm receiving ICA despite <50% stenosis on CTCA
• Proportion of patients assigned to CTCA with normal or mild non-obstructive disease
• Proportion of patients prescribed ACS therapies during index hospitalisation
• Proportion of patients discharged on prevention treatment or who have alteration
in dosage of prevention treatment during index hospitalisation
• Representation or rehospitalisation with suspected ACS/recurrent chest pain within
12 months
• Patient symptoms and quality of life up to 12 months
• Health service resource utilisation
• Patient satisfaction
• Clinician certainty of presenting diagnosis after CTCA
2. Safety • Proportion of patients with allergy/anaphylaxis/acute kidney injury
• Proportion of patients with alternative diagnoses that relate to clinical presentation
identified on CTCA, e.g. aortic dissection or pulmonary embolus
• Proportion of patients with an incidental but potentially concerning finding on CTCA,
e.g. malignancy or pulmonary nodules
• Total average radiation exposure from CTCA in the intervention arm during index
hospitalisation
3. Health economics • Incremental cost per quality-adjusted life year (QALY) gained
Table 2 RAPID-CTCA trial exclusion criteria
1. Signs, symptoms or investigations supporting
high-risk ACS
• ST elevation MI
• ACS with signs or symptoms of acute heart failure
• ACS with signs or symptoms of circulatory shock
• Crescendo episodes of typical anginal pain
• Marked or dynamic ECG changes, e.g. ST depression of >3 mm
• Clinical team have scheduled early ICA on day of trial eligibility assessment
2. Patient inability to undergo CT • Severe renal failure (serum creatinine >250 μmol/L or estimated glomerular filtration
rate <30 mL/min/1.73 m2)
• Contrast allergy
• Beta blocker intolerance or allergy (if no alternative heart rate-limiting agent
available/suitable)
• Inability to hold breath
• Atrial fibrillation (where mean heart rate is anticipated to be greater than 75 beats/min after
beta blockade)
3. Patient had ICA or CTCA within the last 2 years revealing obstructive CAD or patient had ICA or CTCA within the last 5 years
and the result was normal
4. Previous recruitment to the trial
5. Known pregnancy or currently breast feeding
6. Inability to consent
7. Further investigation for ACS would not be in the patient’s interest due to limited life expectancy, quality of life or functional status
8. Prisoners
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these assessments will inform trial eligibility, and the
patient may be approached as soon as they are avail-
able (normally in the first 2 hours after presenta-
tion). Patients may be recruited up to 18 hours after
presentation. This time period has been chosen be-
cause it allows the longest period for recruitment
where the patient could be deemed to be receiving
acute assessment, i.e. up to the point where a 12-
hour troponin result is being used by clinicians for
acute decision making. Patient and clinician will be
unaware of treatment allocation until after screening,
consent and randomisation.
Eligible participants will be asked to provide writ-
ten informed consent by appropriately trained and
delegated members of the research or clinical team.
After assessment for eligibility and consent, the clin-
ical research nurse or a delegated member of the
clinical team will collect the baseline data necessary
to complete the pre-randomisation information.
Table 3 provides a recommended schedule of enrol-
ments, interventions and assessments for this trial.
Randomisation
Randomisation will be performed using a web-based
randomisation service, managed by the Edinburgh
Clinical Trials Unit (ECTU), that ensures allocation
concealment. Once a patient is randomised, he/she
will remain in the study and have all outcomes
recorded regardless of compliance with randomised
pathway allocation, unless the patient specifically
withdraws consent to have data stored. Consented pa-
tients will be randomised on a 1:1 basis to CTCA in
addition to standard care or standard care alone and
will be stratified by study site. This is an open trial.
The patient, recruiting and treating clinicians and
radiologist will not be blinded to the intervention
including the results of the CTCA. Outcome asses-
sors, however, will be blinded to the intervention.
Ineligible and non-recruited patients will receive
standard medical care.
Study interventions
CTCA will be delivered by a trained radiologist or
cardiologist within an established radiology service.
Patients randomised to standard care will receive the
standard management for patients with suspected or
confirmed ACS at that hospital site. The only differ-
ence will be the early use of CTCA in the interven-
tion arm and the subsequent impact on patient care
after the result is provided to the clinician for clin-
ical decision making. Local chest pain management
guidelines will be collected or confirmation obtained
from the site principal investigator (PI) that CTCA
Table 3 Template of recommended content for schedule of enrolment, interventions and assessments for RAPID-CTCA trial
Study period
Enrolment Allocation Post-allocation
Timepoint -t1 0 ≤72 h from
randomisation
Discharge 1 month 6 months 12 months
Enrolment:
Eligibility screen X
Informed consent X
Patient questionnaire X
Vital signs X
Data collection
(secondary endpoints)
X X
Randomisation/allocation X
Interventions:
CTCA (if randomised to CT arm) X
CTCA reporting (CT arm only) X
Clinician questionnaire
(CT arm only)
X
Assessments:
Data collection
(Primary/secondary endpoints)
X X
Patient questionnaire
(data collection secondary endpoints)
X X X
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is not currently in routine use for eligible patients
(including change in practice during the period of
the trial).
The technology being assessed is 64-slice, or
greater, multidetector CT scanners enabled to perform
ECG-gated cardiac studies. The examination may in-
clude a non-contrast ECG-triggered acquisition for
calcium scoring (if part of the local protocol) and a
post-contrast ECG-gated acquisition covering the
whole of the heart and the root of the aorta.
The component of the total research protocol dose
associated with the CTCA scan, i.e. that which is in
addition to normal clinical care, is 10 mSv. This
dose assessment is based on the dose to a typical
patient. There will be normal variation around this
average dose due to individual subjects’ body mass
index (BMI) or heart rate or depending on whether
or not a retrospective gating technique is used. In
these circumstances, the dose may increase to ap-
proximately 30 mSv. Due to the variation in conver-
sion factors used by sites to convert dose-length
product (DLP) to effective dose in millisieverts, the
radiation dose will be routinely reported for the trial
as DLP. A DLP-to-millisieverts conversion factor of
0.014 mSv/mGy/cm will be used for trial reporting
in line with recent publications in this area of re-
search. A typical participant with a heart rate below
70 beats per minute in sinus rhythm and a BMI <25
should therefore have a DLP ≤714 mGy · cm; cases
exceeding this value will be reported as a deviation.
If at any participating centre the DLP regularly ex-
ceeds 1071 DLP mGy · cm, or any DLP exceeds
1428 mGy · cm, this will be reviewed to establish if a
protocol deviation has occurred. All participating
centres will be required to verify that their CTCA
imaging protocol complies with the total research
protocol dose prior to recruitment, and patient doses
will be recorded and monitored as part of the study.
An iodine-based contrast agent will be administered
intravenously using the standard local procedure at
each site. The use of glyceryl trinitrate (GTN) for
coronary artery dilatation will be used at the discre-
tion of individual centres.
CTCA will usually be reported by a trained radiolo-
gist or cardiologist at recruiting centres as soon as
possible, ideally within 2 hours of the scan, and the
results immediately communicated to the treating
clinician. The clinical report detailing the results
should be reported according to the Society of
Cardiovascular CT guidelines, with the use of the
American Heart Association coronary artery segment
model, and will include both the calcium score if cal-
culated and the presence of cardiac and non-cardiac
findings. Stenoses will be quantified as no significant
CAD (estimated stenosis <10%), mild non-obstructive
CAD (estimated stenosis of 10–49%), moderate non-
obstructive CAD (estimated stenosis of 50–70%) or
obstructive CAD (estimated stenosis of >70%).
A proportion of CTCA reporting may be delivered
remotely using remote access technology by a core
group of readers. Transfer of image data is a well-
established process within the UK for out-of-hours
radiology reporting. Secure electronic transfer via the
national Picture Archiving and Communication
System (PACS) system (with required permissions)
will allow reporting using voice recognition dictation
either directly to the host radiology information
system or via email directly to the referring centre.
A proportion of scans will be separately reported by
experts independent to the trial and blinded to the
initial report to measure inter-observer reliability. The
first 10 scans performed at each site will undergo this
process as well as a 5% random sample of the
remaining scans.
Impact of CTCA on participant management
CTCA results will be available to the clinical team to
support acute clinical decision making. The provision of
immediate CTCA with early reporting is expected to be
variable across the centres. The intervention will be
delivered by routine clinical staff. It is anticipated that
60–70% of patients will be recruited between 8.00 am
and 6.00 pm and will be eligible for immediate CTCA
[30]. Patients recruited to the study and randomised to
CTCA will receive a CTCA as soon as feasible, and
normally on the day of or day following randomisation,
providing this does not significantly delay routine pro-
cesses of care including discharge. Where a clinical deci-
sion is made to discharge the participant before the scan
takes place, they will be asked to return for ambulatory
CTCA within 72 hours and then be reviewed in the ED,
MAU or cardiology department, depending on local
procedures.
The results of the CTCA are likely to influence
subsequent management. A guideline has been devel-
oped which will be available to clinicians to guide
subsequent management dependent on the CTCA
result (Appendix 1). A template letter is available to
clinicians, if they wish to use it, to inform the pa-
tient’s primary care physician about non-obstructive
CAD identified by the CTCA that may require sec-
ondary prevention being implemented by the primary
care physician.
All other management and admission or discharge
decisions will be at the discretion of the treating cli-
nicians. Sites will be requested not to use CTCA as
part of the routine investigation of ACS, and this will
be closely monitored.
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Participant follow-up
Patients will normally be followed up using routine clin-
ical notes and research contact directly with the patient
by phone, email or post. At organisations where it is not
possible to routinely get this data from administrative
health service records, the research team at the site will
attempt to contact the participant and/or their general
practitioner (GP) by telephone to obtain the 12-month
follow-up data. All patients will be followed up for
1 year.
Study participants are free to withdraw from the
trial at any time. For patients who withdraw from
active follow-up, routine data will continue to be
collected unless the patient requests otherwise. The
patient may be willing to give a reason for with-
drawal, but this is not obligatory. Reasons, if given,
will be recorded, and data collected up to that
timepoint may be used in the final analyses, unless
the patient specifically requests that their data not be
used. If the patient withdraws consent to have their
data stored, then this will be documented on the trial
Consolidated Standards of Reporting Trials (CON-
SORT) flow diagram as ‘withdrawn’ and their data
will not be used in the final analyses.
Any patient in the control group who has a CTCA
as part of routine care within 30 days of randomisa-
tion will be defined as a crossover and will not be
recorded as a deviation. Non-adherence will be de-
fined as to have occurred in any participant not re-
ceiving a reported CTCA if randomised to it within
72 hours, and this would be recorded as a deviation.
This allows ambulatory CTCA to be delivered when
appropriate. Individual site retention, crossover and
non-adherence will be monitored and reviewed at the
Project Management Group (PMG) and Trial Steering
Committee (TSC) meetings.
Data collection
Data will be collected by the research team from
routinely available administrative records or trial-
specific documentation and will include the following
categories: eligibility criteria, consent and baseline
demographics, comorbidities, regular treatment, ECG
results, vital signs, blood results, admission and
discharge diagnoses, cardiology and other relevant
investigations or interventions, length of stay, repeat
hospitalisations and adverse events. Detail will also be
collected on the trial intervention including timing,
details of the procedure including dose, reporting
clinician, report including incidental findings and any
adverse events as a result of the intervention.
Length of stay and major adverse cardiac events will
be recorded from telephone contact with patients,
hospital and primary care records and death records
from the Central Registry Office or equivalent. At
baseline and at 1, 6 and 12 months, quality of life
and angina symptoms will be measured using the
EuroQol EQ-5D-5 L and Rose questionnaires by
direct patient interview, postal or email survey with
telephone follow-up for non-responders after two
mailings 2 weeks apart.
Statistical analysis and sample size calculation
One-year death or recurrent MI rate for this patient
group is ~20% [11]. A total of 2424 evaluable pa-
tients are required (1212 per arm) to have 90%
power to detect a 20% versus 15% difference in 1-
year death or recurrent MI rate based on two-sided
p < 0.05 using a chi-squared test. With a 3% drop-
out rate, the sample size will be 2500 patients.
Reviewing UK patient characteristics and presenta-
tion data, we estimate from previous data that there
will be approximately 7000–8000 eligible patients an-
nually across approximately 35 UK centres [11, 31,
32]. Although we anticipate and will aim for a
higher recruitment rate than the 20% detailed below,
our experience of emergency medicine trials has re-
sulted in a conservative approach to estimation of
recruitment rates. If we were to recruit 20% of these
eligible patients and if all 35 centres recruited for
2 years, the trial would recruit about 3000 partici-
pants. We therefore believe, given the complexities
of delivering this trial, that recruiting 2500 patients
in about 35 centres over 2 years is feasible: about 1
patient per site, per week.
The trial will be reported on an intention-to-treat
basis. The primary outcome is defined as first event
of all-cause death or recurrent non-fatal MI type 1 or
4b. Time to primary outcome is defined as time from
randomisation to primary outcome. Patients discon-
tinuing the study (for any reason) prior to reaching
primary outcome will have their time to primary out-
come censored at the last contact date. The relation-
ship between intervention and the primary outcome
will be analysed using Cox proportional hazard re-
gression adjusted for study site (used to stratify the
randomisation), age, baseline Global Registry of Acute
Coronary Events (GRACE) score, previous CAD and
baseline troponin level. The results will be expressed
as a hazard ratio with the corresponding 95% confi-
dence intervals and p value. The individual elements
of the composite primary outcome will be reported
separately.
Subgroup analysis on the primary outcome is
planned for age, baseline GRACE score, previous
CAD and baseline troponin concentration. These
will be assessed by examining the effect of entering
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the treatment by subgroup interaction into the Cox
regression model. Secondary outcomes will be ana-
lysed using appropriate methods: logistic regression
for binary outcomes and linear regression for nor-
mally distributed continuous outcomes, adjusted as
described above. Continuous outcomes that are not
normally distributed will be analysed using appropri-
ate non-parametric techniques. The primary analysis
will be intention-to-treat. Every effort will be made
to minimise missing data, and our primary analysis
will be a complete case analysis. If there is a suffi-
cient level of missing data to affect our conclusions,
a multiple imputation analysis will be undertaken,
using clinically appropriate variables, as a sensitivity
analysis. A full statistical analysis plan will be writ-
ten during the trial and finalised prior to database
lock.
Economic analysis
Economic evaluation will assist policy makers in de-
ciding whether multidetector CT scanning represents
a cost-effective use of health service resources. The
economic analysis will include (1) a within-trial cost
effectiveness analysis (i.e. comparing the observed
costs and QALYs of the intervention and control
groups during the trial period) and (2) an analysis of
the long-term cost effectiveness of CTCA, adapting
an existing decision analytic model [18, 33].
In the within-trial cost-effectiveness analysis, incre-
mental cost per QALY gained by using CTCA
compared to standard care will be estimated by cal-
culating the area under the curve for health utility
using the EQ-5D-5 L and health service costs up to
1 year. Quality of life and angina symptoms will be
measured using the EQ-5D-5 L and Rose question-
naires (see above) at baseline and at 1, 6 and
12 months after index admission. All health care
consumption and costs will be estimated from a so-
cietal perspective using patient self-reported ques-
tionnaires and from hospital records. Costs will be
attributed to the need for (1) continued hospitalisa-
tion, (2) additional invasive or non-invasive imaging,
(3) drug therapy and (4) rehospitalisation for myo-
cardial ischaemia. Costs of hospital admission will be
measured using a top-down costing strategy. These
costs will be measured for each patient in the trial
and multiplied by national average costs to provide
the estimated cost per patient. Local unit costs for
staff and consumables will be obtained from each
hospital finance department.
Long-term cost effectiveness will be estimated by
adapting an existing model, developed as part of a
previous evidence synthesis project [18, 32]. The
model used published sources to capture patients’
life expectancy, annual costs and corresponding an-
nual utilities, based on whether they had MI at ini-
tial hospital attendance and whether they suffered
reinfarction. The data from the trial will be input
into the model to estimate the lifetime QALYs and
costs of surviving patients. The results will be re-
ported as the incremental cost-effectiveness ratio
(ICER) of the CTCA arm compared to usual care.
Sensitivity analyses will explore the potential im-
pact of parameters upon costs, QALYs and ICERs.
Parameter uncertainty will be included in a probabil-
istic sensitivity analysis based on Monte Carlo
simulation. Cost-effectiveness acceptability curves
(CEACs) will be plotted to identify the probability of
the CTCA arm being cost effective compared to
standard care for a range of willingness-to-pay values
for an additional QALY.
Trial oversight, ethics and governance
The trial has been reviewed and approved by the South
East Scotland Research Ethics Committee (14/SS/1096).
The Academic and Clinical Central Office for Research
and Development (ACCORD) in Edinburgh is providing
sponsorship and monitoring oversight for the project,
and the trial will be conducted in line with the relevant
sponsor standard operating procedures (SOPs). The
ECTU is responsible for trial management, oversight of
data collection and statistical analysis. The University of
Sheffield is responsible for the health economics ana-
lysis. A PMG comprising the applicants and relevant
members of the ECTU team will provide ongoing trial
support. A writing committee will be formed by mem-
bers of the PMG, and they will have responsibility for
interpreting the data and writing and reviewing the final
report. A draft of the final study report will be sent to
the funder for peer review prior to submission for publi-
cation. A TSC and Data Monitoring Committee (DMC)
have been established to oversee the safety, conduct and
progress of the study. Appendix 2 details the RAPID-
CTCA trial registration details.
Discussion
The RAPID-CTCA trial will recruit 2500 participants
across about 35 hospital sites is the first study to in-
vestigate the role of CTCA in the early assessment
of patients with suspected or confirmed ACS who
are at intermediate risk, including patients who have
raised troponin measurements during initial assess-
ment. All previous ED trials have enrolled patients
who are at low risk of ACS, supported by the excep-
tionally low subsequent 30-day and 1-year reported
outcomes. Three recent trials in stable patients have
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demonstrated improved accuracy of diagnosis, an
increase in downstream cardiological investigations
including ICA and improved longer term cardiovas-
cular outcomes in patients randomised to CTCA, al-
though none of these trials was powered for these
outcomes [18–20]. The CATCH trial in 600 patients
with chest pain assessed for ACS in a single centre
in Denmark further supports these findings with the
recent reporting of the longer term clinical outcomes
[26, 27]. They reported that CTCA was associated
with better selection of patients for ICA with a
lower rate of normal ICA results despite greater use
of ICA. CTCA led to an increased use of preventa-
tive therapies and substantially more PCI at the
index assessment. Lastly, a recently published trial
from seven Dutch EDs did not show any short-term
differences between standard care using high-
sensitivity troponin assays alone or with the addition
of CTCA, other than a reduction in downstream in-
vestigations [28]. This perhaps suggests that, with an
optimised biomarker strategy in patients with no
prior history of CAD or other higher risk features,
CTCA is unlikely to affect clinical outcomes.
There have been a number of challenges in the
set-up and delivery of the RAPID-CTCA trial. In the
UK, the assessment and management of acute chest
pain is truly multispecialty treatment (emergency
medicine, acute and general medicine and cardi-
ology), and this may vary considerably between sites
and specialties within sites. In many centres, most
patients receive no ancillary testing if they do not
have high-risk features, and for many, ongoing care
is provided by their primary care physician. Radi-
ology access in terms of the types of investigations
available, time of access and which specialties rou-
tinely have access to them also varies considerably
between sites. This becomes even more complex in
the context of a trial competing with other patients
for scarce resources, in particular CT scanning within
a target-driven system. Concerns regarding the risk of ra-
diation exposure have also been an issue, especially as it
has been perceived that, in this ’higher’ risk group, pa-
tients may receive radiation from both a CT and subse-
quent ICA. These issues have resulted in site engagement
for the trial being far more complex and time-consuming
than if the trial were being undertaken by a single spe-
cialty and has resulted in protracted set-up timelines and
the placement of significant limits on recruitment due to
resources.
If a trial of a diagnostic intervention such as CTCA is
to result in change in clinical outcomes, it must influ-
ence downstream treatment. In patients with suspected
or confirmed ACS this is likely to be due to higher rates
of appropriate early coronary intervention after CT has
defined the extent of disease, and in the longer term
greater cardiological input and the use of preventative
treatments for those patients with non-obstructive CAD.
Early CTCA needs investigation in intermediate-
risk ACS patients where improved and optimal tar-
geting of interventions, including coronary revascu-
larisation, and primary and secondary preventive
therapy is likely to improve diagnosis and longer
term outcome. The clinical and cost effectiveness of
early CTCA in suspected or confirmed ACS must be
clearly demonstrated before adoption of the technol-
ogy into routine practice, given its cost, risk and
uncertainty of benefit. A positive or negative trial,
therefore, is equally important.
Trial status
The trial opened to recruitment in March 2015 with
34 UK sites participating in April 2016. Recruitment
is anticipated to run until 30 June 2017 with trial
completion by 31 December 2018. As of May 2016,
15% of the study population was recruited.
Appendix 1
Table 4 presents the guideline for clinicians for subse-
quent management dependent on the CTCA result.
Table 4 Management guideline for trial intervention arm
CTCA result Troponin
result
Trial treatment recommendation
Obstructive disease:
stenosis ≥70%
Positive or
negative
1. ACS and secondary
preventative therapies
2. Invasive coronary angiography
(ICA) ± revascularisation
Moderate
non-obstructive
disease: stenosis
50–69%
Positive 1. ACS and secondary
preventative therapies
2. Consider ICA if uncertainty
about the presence of
obstructive coronary
artery disease or
functional testing
Moderate
non-obstructive
disease: stenosis
50–69%
Negative 1. Secondary preventative
therapies
2. Consider ICA if uncertainty
about the presence of
obstructive coronary artery
disease or functional testing
Mild non-obstructive
disease: stenosis <50%
Positive 1. Consider ACS and secondary
preventative therapies
2. Consider alternative
cause of chest pain
and troponin rise
Mild non-obstructive
disease: stenosis <50%
Negative 1. Discharge with no further
follow-up
2. Consider secondary
preventative therapies
Normal (no evidence
of CAD)
Discharge with no further
follow-up
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Appendix 2
Table 5 summarizes the registration details for this trial.
Table 5 Summary of key trial registration details
Data category Information
Primary registry and trial
identifying number
ISRCTN19102565
Date of registration in primary
registry
03/10/2014
Secondary identifying numbers NCT02284191
Source(s) of monetary or material
support
National Institute for Health Research Health Technology Assessment Programme
Primary sponsor Co-sponsored by University of Edinburgh and NHS Lothian (ACCORD)
Secondary sponsor(s) N/A
Contact for public queries rapid.ctca@ed.ac.uk
Contact for scientific queries Alasdair.gray@nhslothian.scot.nhs.uk
Public title Rapid Assessment of Potential Ischaemic Heart Disease with CTCA (the RAPID-CTCA trial)
Scientific title The role of early CT coronary angiography in the evaluation, intervention and outcome of patients presenting to
the emergency department with suspected or confirmed acute coronary syndrome
Countries of recruitment UK
Health condition(s) or problem(s)
studied
Acute coronary syndrome
Intervention(s) CT coronary angiography
Key inclusion and exclusion
criteria
INCLUSION CRITERIA
Patient ≥18 years with symptoms mandating investigation for suspected or confirmed ACS with at least one of
the following: ECG abnormalities, e.g. ST-segment depression >0.5 mm; history of ischaemic heart disease (where
the clinician assessing patient confirms history based on patient history or available records); troponin elevation
above the 99th centile of the normal reference range or increase in high-sensitivity troponin meeting European
Society of Cardiology criteria for ‘rule-in’ of myocardial infarction (NB troponin assays will vary from site to site;
local laboratory reference standards will be used).
EXCLUSION CRITERIA
1. Signs, symptoms or investigations supporting high-risk ACS: ST elevation MI; ACS with signs or symptoms of
acute heart failure or circulatory shock; crescendo episodes of typical anginal pain; marked or dynamic ECG
changes, e.g. ST depression of >3 mm; clinical team have scheduled early invasive coronary angiography on
day of trial eligibility assessment
2. Patient inability to undergo CT: severe renal failure (serum creatinine >250 μmol/L or estimated glomerular
filtration rate <30 mL/min); contrast allergy; beta blocker intolerance (if no alternative heart rate-limiting agent
available/suitable) or allergy; inability to hold breath; atrial fibrillation (where mean heart rate is anticipated to
be greater than 75 beats/min after beta blockade)
3. Patient has had ICA or CTCA within last 2 years revealing obstructive coronary artery disease, or patient had
either investigation within the last 5 years and the result was normal.
4. Previous recruitment to the trial
5. Known pregnancy or currently breast feeding
6. Inability to consent
7. Further investigation for ACS would not be in the patient’s interest, due to limited life expectancy, quality of life
or functional status
8. Prisoners
Study type Open parallel randomised controlled trial
Date of first enrolment 23/03/2015
Target sample size 2500
Recruitment status Open
Primary outcome(s) The primary endpoint will be all-cause death or recurrent non-fatal type 1 or type 4b MI at one year and time to
first such event. MI will be defined according to the most recent Universal Definition [13] and will be adjudicated
by two independent cardiologists blinded to the intervention
Key secondary outcomes 1. Hospital length of stay, coronary care length of stay
2. Proportion of patients receiving ICA during index hospitalisation
3. Proportion of patients receiving coronary revascularisation during index hospitalisation
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Table 5 Summary of key trial registration details (Continued)
4. Proportion of patients receiving subsequent unplanned coronary revascularisation after index hospitalisation
within 12 months
5. Proportion of patients in CTCA arm receiving ICA despite <50% stenosis on CTCA
6. Proportion of patients assigned to CTCA with normal or mild non-obstructive disease
7. Proportion of patients prescribed ACS therapies during index hospitalisation
8. Proportion of patients discharged on prevention treatment or who have alteration in dosage of prevention
treatment during index hospitalisation
9. Representation or rehospitalisation with suspected ACS/recurrent chest pain within 12 months
10. Patient symptoms and quality of life up to 12 months
11. National Health Service (NHS) resource utilisation
12. Patient satisfaction
13. Clinician certainty of presenting diagnosis after CTCA
SAFETY
1. Proportion of patients with allergy/anaphylaxis/acute kidney injury
2. Proportion of patients with alternative diagnoses that relate to presentation on CTCA, e.g. aortic dissection or
pulmonary embolus
3. Proportion of patients with incidental but potentially concerning finding on CTCA, e.g. malignancy or
pulmonary nodules
4. Total average radiation exposure from CTCA in the intervention arm during index hospitalisation
Cost effectiveness: estimated in terms of the incremental cost per quality-adjusted life year (QALY) gained
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